- 01Q-Jun cash flow: $7.7m; receipts $24.6m; FY cash flow $6.8m.
- 02UH Sussex Miya upfront: $35m; 7y; UK's largest EPR.
- 03FY26: rev ~51.6m; EBITDA >5m.
Healthcare technology developer Alcidion Group (ASX: ALC) has reported record positive operating cash flow for the three months to end June of $7.7 million, driven by quarterly cash receipts of $24.6m and resulting in full-year positive operating cash flow of $6.8m.
The receipts included a $10.6m payment from University Hospitals Sussex NHS Foundation Trust covering an upfront capital licence fee for the Miya Precision clinical software platform after the parties signed a seven-year contract in January valued at $35m.
UH Sussex is Alcidion’s third electronic patient record (EPR) deployment in the UK and will be the largest trust to deploy the AI-powered platform for full EPR capabilities.
Total contract value sales and renewals totalled $43.2m for the period, including the UH Sussex deal and a four-year (plus one) contract extension with Victoria’s Western Health public healthcare network for continued use of Miya Precision and expansion of patient flow, access and command modules to additional beds.
High Operating Costs
Alcidion’s product manufacturing and operating costs stayed high for the period at $4.1m, reflecting payments for the upfront licence component for third-party partner products associated with the UH Sussex contract.
Staff cash costs also increased slightly in the quarter after the company advanced the payment of 50% of short-term incentives achieved during the 2026 financial year.
Alcidion completed the acquisition of Kyra flow products from Telstra Health in June, adding 33 customers to its books and further underpinning its position as a leading provider of patient flow solutions in Australia-New Zealand and the UK.
Investing cash flow activities included the net completion payment of $1.5m for the Kyra flow acquisition, reflecting the upfront consideration of $3m less completion adjustments for a cash-free and debt-free transaction.
FY26 Guidance Confirmed
Alcidion has reconfirmed “with a high degree of confidence” its FY26 financial guidance of approximately $51.6m revenue and EBITDA above $5.0m.
“Positive operating cash flow highlights a strong EBITDA-to-cash flow conversion, which has been a consistent highlight of our business and builds upon our cash balance for future growth opportunities,” managing director Kate Quirke said.
“Our operational milestones continue to create new opportunities within established markets and enable us to further expand our position as one of the leading providers of modern and modular enterprise solutions to acute healthcare organisations.”
The company will provide a detailed update as part of its full year FY26 results scheduled to be released during the second half of August.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.